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Summary Although epidemiological studies of the relationship between cigarette smoking and colorectal
cancer risk have been equivocal, a positive association is consistently found for colorectal adenoma
development. We performed an epidemiological study to determine whether p53 protein overexpression, in
tumours obtained at the time of resection, is associated with cigarette exposure in colorectal cancer. A total of
163 colorectal cancer cases and 326 healthy controls responded to a standardised questionnaire on colorectal
cancer risk factors including detailed information on their history of cigarette smoking. All patients' tumours
were analysed immunohistochemically for p53 overexpression using an avidin-biotin immunoperoxidase
procedure and polyclonal anti-p53 antibody CM 1. Comparison of colorectal cases with controls revealed an
elevated risk for ex-smokers (OR= 1.34, 95% CI 0.85-2.12) and current smokers (OR= 1.13, 95% CI 0.63-
2.02) when compared with non-smokers. No dose-response relationship was found for total pack-years of
smoking (trend test: P=0.19). However, a trend for total pack-years of smoking was found when p53-positive
cases were compared with p53-negative cases suggesting aetiological, heterogeneity (trend test: P=0.06).
Estimating the individual relative risk of developing a p53-positive tumour relative to controls showed no
associations for smoking status or total pack -years of smoking. However, when p53-negative cases were
compared with controls, an elevated risk was found for ex-smokers (OR= 1.84, 95% CI 1.00-3.37) and current
smokers (OR= 1.78, 95% CI 0.88-3.61). A significant trend of increasing risk was also found for total pack-
years of smoking (trend test: P=0.03). Colorectal tumours developing through p53-positive dependent
pathways were not associated with smoking exposure. A significant increase in risk was observed for the p53-
negative independent pathway with smoking. p53 overexpression appears to be associated with smoking
exposure in colorectal cancer.
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Cigarette smoking is known to contribute to the development
of many cancers. Results from epidemiological studies
investigating its role in colorectal cancer have been
inconsistent. Whereas some case-control studies have
demonstrated an increased risk (Martinez et al., 1981; Dales
et al., 1979; Vobecky et al., 1983; Kabat et al., 1986;
Jarebinski et al., 1988, 1989; Slattery et al., 1990; Kune et al.,
1992a), others find no association (Wynder et al., 1969;
Haenszel et al., 1973; Williams and Horm, 1977; Graham et
al., 1978; Jain et al., 1980; Tuyns et al., 1982; Ferraroni et al.,
1989; Olsen and Kronberg, 1993), or a reduction in risk
(Higginson, 1966; Wynder and Shigematsu, 1967; Stazewski,
1969; Haenszel et al., 1980; Papdimitriou et al., 1984; Tajima
and Tominaga, 1985; Peters et al., 1989; Choi and Kahyo,
1991). In contrast, studies of the relationship between
smoking and colorectal adenomas have consistently observed
a positive relationship (Olsen and Kronberg, 1993; Zahm et
al., 1991; Honjo et al., 1992; Kikendall et al., 1991; Hoff et
al., 1987; Monnet et al., 1991; Lee et al., 1993; Sandler et al.,
1993; Kune et al., 1992b; Demers et al., 1988; Cope et al.,
1991; Martinez et al., 1995; Drexler, 1971). To explore these
divergent findings, data from two recent cohort studies were
examined (Giovannucci et al., 1994a and b). Results from
both studies were similar and suggest that smoking may act
as an initiator of colorectal carcinogenesis. Previous studies
may have yielded equivocal results because they failed to
allow for the presumably long induction period between
smoking onset and colorectal neoplasia.
Carcinogens present in cigarette smoke cause DNA
damage and may produce specific mutations. Alterations of
TP53 is the most frequent molecular abnormality found in
human cancer and is a susceptible target for many exogenous
carcinogens and endogenous mutagens in a variety of
tumours (Hollstein et al., 1991a; Harris, 1991; Bennett et
al., 1991). Mutation of TP53 induces loss of tumour-
suppressor functions and usually results in the overexpres-
sion of mutant p53 protein (Lane, 1990). Overexpression of
p53 protein can be detected by immunohistochemistry and
correlates well with TP53 mutation (Cordon-Cardo et al.,
1994; Umekita et al., 1994). Mutations and overexpression of
p53 have been associated with a history of cigarette exposure
in cancers where p53 alterations are an early occurrence in
carcinogenesis such as lung (Suzuki et al., 1992; Miller et al.,
1992), head and neck (Field et al., 1991, 1994), oesophageal
(Hollstein et al., 1991b), and bladder cancer (Spruck et al.,
1993; Zhang et al., 1994a).
Colorectal carcinogenesis is a multistep process involving
adenoma formation and progression to carcinoma due to
mutational activation of oncogenes and inactivation of
tumour suppressor genes (Fearon and Vogelstein, 1990).
Alteration of TP53 genes is a late event in the adenoma-
carcinoma sequence and occurs before the transition of large
adenomas to carcinomas (Fearon, 1993).
Given that colorectal adenomas are regarded as precursors
of cancer, the repeatedly observed positive association
between smoking and adenomas, but not cancer, is
puzzling. The possibility exists that tumours acquiring
genetic alterations late in the adenoma-carcinoma sequence
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may be unrelated to smoking exposure and may distort
results of studies examining the relationship between smoking
and colorectal cancer risk. To examine the hypothesis that
tumour formation via the p53 (p53 negative) independent
pathway is more strongly associated with smoking than p53
(p53 positive) dependent pathways, we analysed smoking
exposure among 163 colorectal cancer patients with respect to
p53 overexpression.
Materials and methods
Patient population
Patients diagnosed with a first primary sporadic colorectal
cancer at Roswell Park Cancer Institute and Buffalo General
Hospital in Buffalo, NY, USA between 1982 and 1993 were
asked to complete an extensive questionnaire soliciting
information on family history of cancer, tobacco use and
other lifestyle behaviours. Patients who completed the
questionnaire and had paraffin-embedded tumour specimens
available for p53 immunohistochemical analysis were eligible
for study. Using these criteria, 163 colorectal cancer patients
qualified for evaluation.
Control population
Between 1982 and 1987, over 2500 patients admitted to
Roswell Park Cancer Institute with non-malignant diseases or
visiting the screening clinic, were also routinely asked to
complete an epidemiological questionnaire. For this study a
total of 326 controls were used, with the majority (256/326)
made up of healthy screening clinic visitors. All colorectal
cancer controls were matched to cases by gender and age
within five years.
Exposure
Subjects were categorised as current smokers, never smokers,
or ex-smokers (if they stopped five or more years before). To
determine total lifetime smoking, a cumulative cigarette pack-
year history was calculated for each subject. One pack-year
of smoking is equivalent to having smoked one pack (20
cigarettes) per day for an entire year.
Immunohistochemical method
Formalin-fixed, paraffin-embedded tissue sections from the
tumours were analysed immunohistochemically for altered
patterns of p53 expression, using a standard avidin-biotin
technique. Sections (4 gim thick) were deparaffinised in xylene,
rehydrated in a graded ethanol series and incubated in 3%
hydrogen peroxide for 20 min. After rinsing in phosphate-
buffered saline (PBS) pH 7.4, sections were incubated for
15 min in boiling distilled water to promote antigen retrieval of
masked antigens (Shi et al., 1991). Tissue sections were blocked
in 2% normal goat serum and then incubated overnight at 4°C
with NCL-p53-CM1 antibody (Novacastra Laboratories, UK)
at a dilution of 1: 1000. This antibody is a rabbit polyclonal
antibody that detects both wild-type and mutant forms ofp53.
Sections were then incubated with biotinylated goat anti-rabbit
antiserum (Vector Laboratories, Burlingame, CA) for 45 min,
then with ABC reagent (avidin-biotin peroxidase complex,
Vectastain Elite Kit, Vector Laboratories) for 30 min.
Immunoreaction was developed for 6 min using a solution
containing 0.5 mg ml-' 3,3'-diaminobenzidine tetrahy-
drochloride and 0.03% hydrogen peroxide. Tissue sections
were counterstained with light haematoxylin, dehydrated with
ethanol, cleared with Histo-Clear (National Diagnostics,
Manville, NJ), and mounted under a coverslip. Sections
known to stain positively were included in each run, receiving
either primary anti-p53 antibody or PBS as positive and
negative controls, respectively.
The slides were scored independently by two pathologists
(JEA, SS) without any clinical or pathological information.
Tumours were classified as p53 negative if 0- 19% of cells
displayed nuclear positivity and p53 positive if greater than
or equal to 20% of cells were positive for nuclear p53.
Staging of all tumours was performed (NJP) according to the
TNM pathological staging system.
Statistical analysis
Associations between disease and cigarette smoking were
measured using odds ratios (OR) and 95% confidence
intervals (CI). Unconditional logistic regression analysis was
used to obtain maximum likelihood estimates of odds ratios
and their 95% confidence intervals after controlling for
gender, age (<55, 55-64, 65-74, >75 years), family history
of colorectal cancer, body mass index and alcohol,
cruciferous vegetable and meat consumption (Breslow and
Day, 1980). To assess dose-response relationship, smoking
exposure was classified by total pack-years of smoking in
four categories: (1) non-smoking, (2) 1 -19 pack-years, (3)
20-39 pack-years, (4) >40 pack-years. Trend tests were
performed by assigning the scorej to thejth exposure level of
a categorical variable, and treating it as a continuous variable
in the logistic model.
To examine aetiologic heterogeneity, odds ratios were
calculated for the association between p53 nuclear overexpres-
sion and smoking. This odds ratio is the odds of smoking
exposure in the p53-positive group divided by the odds of
smokingexposureinthep53-negativegroup. Eachoftheseodds
ratiosrepresentstheratio oftherelativeriskofsmokingforp53-
positive tumoursto therelative riskofsmokingforp53-negative
tumours. Aetiological heterogeneity is indicated by departures
from the value of 1 (Begg and Zhang, 1994).
With healthy controls used as the referent group, three
additional comparisons were made. First, standard analysis
was conducted comparing all colorectal cases with controls. To
estimate the risk of developing a colorectal tumour through a
p53 (positive) dependent pathway, only colorectalpatients with
p53+ overexpression werecompared with controls. To estimate
the risk of developing a colorectal tumour through a p53
(negative) independent pathway, colorectal patients with p53-
overexpression were compared with controls.
Results
Characteristics ofpatients
Nineteen per cent of the patients were less than 55 years of
age, 29% were between the ages of 55 and 64 years, 34%
were between 65 and 74 years old and 17% were 75 or older.
Fifty-six per cent (91/163) of the subjects were males and
96% (157/163) were white. Forty-seven per cent (77/163) of
patients' tumours were located in the rectum or rectosigmoid
regions of the large bowel. Patient tumour distribution by
TNM stage consisted of 26% stage 0/I, 23% stage II, 34%
stage III, and 16.5% stage IV.
p53 nuclear overexpression
Nuclear overexpression of p53 protein in 20% or more of the
cells was found in 44.8% (73/163) of colorectal tumours.
None of the mucosa adjacent to tumour showed any
detectable nuclear reactivity. Neither gender, age nor tumour
stage differed with respect to p53 overexpression (Table I).
Patients with a positive family history of colorectal cancer
were more likely to have p53- tumours (P<0.05). Of the 31
patients reporting a positive family history, only nine
displayed p53 nuclear reactivity in their tumours, compared
with 64 of 128 patients without a family history of colorectal
cancer.
Case-control comparison
Among the 163 patients, 162 (99%) provided a complete
smoking history. All 326 controls reported their use ofSmoking and p53 in colorectal cancer
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tobacco. Odds ratios for smoking status and total pack-
years of smoking adjusted for gender, age, family history of
colorectal cancer, body mass index and alcohol, cruciferous
vegetables and meat consumption are presented in Table II.
Ex-smokers (OR= 1.34, 95% CI 0.85-2.12) and current
smokers (OR= 1.13, 95% CI 0.63 -2.02) were observed to be
at increased risk when compared with non-smokers. A
significant dose-response relationship was observed for
total pack-years of smoking after controlling for age,
gender and family history (trend test: P=0.05). However,
after adjusting for dietary risk factors, the dose-response
relationship no longer remained statistically significant (trend
test: P=0.19).
However, markedly different results were found when p53-
cases were compared with controls. Elevated risks were
observed for ex-smokers (OR= 1.84, 95% CI 1.00-3.37) and
current smokers (OR= 1.78, 95% CI 0.88-3.61) when
compared with non-smokers. Moreover, a significant trend
of increasing risk was observed for total pack-years of
smoking (trend test: P=0.03). An odds ratio of 2.72 (95% CI
1.38-5.36) for 20-39 pack-years of smoking and an odds
ratio of 1.68 (95% CI 0.83-3.39) for >40 pack-years was
observed when compared with non-smokers.
Discussion
Smoking exposure and p53 overexpression
Nuclear overexpression of the p53 protein was observed in
29% (33/59) current smokers, 42.3% (30/71) ex-smokers and
55.9% (33/59) of non-smokers. The association between
smoking status and p53 overexpression resulted in an odds
ratio of 0.60 (95% CI 0.28-1.31) for ex-smokers and 0.35
(95% CI 0.12-0.98) for current smokers when compared
with non-smokers (Table III). A dose-response relationship
was observed with categories of total pack-years of smoking
after controlling for potential confounders (trend test:
P=0.06). No significant associations or trends were
observed for smoking status or total pack-years of smoking
when p53+ cases were compared with controls (Table IV).
Table I Distribution of colorectal cancer patients' tumours for p53
overexpression according to gender, age, TNM stage and family
history of colorectal cancer
%pS3 + overexpression
42.9 (39/91)
47.2 (34/72)
44.4 (12/27)
45.8 (22/48)
50.0 (28/56)
39.3 (11/28)
47.5 (19/40)
28.6 (10/35)
50.0 (26/52)
56.0 (14/25)
Family history of colorectal cancera
Positive
Negative
ap<O.S.
29.0 (9/31)
50.0 (64/128)
Epidemiological studies have not found a consistent
association between colorectal cancer risk and tobacco use.
Both case control and cohort studies have reported conflict-
ing findings (Martinez et al., 1981; Dales et al., 1979;
Vobecky et al., 1983; Kabat et al., 1986; Jarebinski et al.,
1988, 1989; Slattery et al., 1990; Kune et al., 1992a; Wynder
et al., 1969; Haenszel et al., 1973, 1980; Williams and Horm,
1977; Graham et al., 1978; Jain et al., 1980; Tuyns et al.,
1982; Ferraroni et al., 1989; Olsen and Kronberg, 1993;
Higginson, 1966; Wynder and Shigematsu, 1967; Stazewski,
1969; Papdimitriou et al., 1984; Tajima and Tominaga, 1985;
Peters et al., 1989; Choi and Kahyo, 1991; Giovannucci et al.,
1994a and b; Cartensen et al., 1987; Chute et al., 1991; Doll
et al., 1980; Doll and Peto, 1976; Garland et al., 1985;
Hammond, 1966; Hammond and Horn, 1958; Hirayama,
1975; Kahn, 1966; Klatsky et al., 1988; Kono et al., 1987;
Rogot and Murray, 1980; Sandler et al., 1988; Tverdal et al.,
1993; Weir and Dunn, 1970; Williams et al., 1981; Wu et al.,
1987; Heineman et al., 1995). Results from our case control
comparison reveal elevated risks for former (OR= 1.34, 95%
CI 0.85-2.12) and current smokers (OR= 1.13, 95% CI
0.63-2.02), and a non-significant dose-response relationship
for total pack-years of smoking (trend test: P = 0.19).
Unlike the case of colorectal cancer risk, positive
associations between tobaccco use and adenomatous polyp
development have been reported in 14 of 15 studies (Olsen
and Kronberg, 1993; Zahm et al., 1991; Honjo et al., 1992;
Kikendall et al., 1991; Hoff et al., 1987; Monnet et al., 1991;
Lee et al., 1993; Sandler et al., 1993; Kune et al., 1992b;
Demers et al., 1988; Cope et al., 1991; Martinez et al., 1995;
Drexler, 1971; Giovannucci et al., 1994a and b). This
incongruity is surprising since adenomas are thought to be
precursors of cancer. To clarify this issue, Giovannucci and
colleagues examined the association between cigarette
smoking with both colorectal adenoma and carcinoma in
two separate cohort studies encompassing over 35 years of
follow-up (Giovannucci et al., 1994a and b). The authors
report that small adenomas may be associated with less than
20 years of smoking, larger adenomas may require 20 years
of smoking exposure and colorectal cancers are associated
Table II Colorectal cancer risk for smoking status and pack-years of smoking
Cases Controls OR (95% CI)a OR (95% CI)b
Smoking status
Non-smoker 59 145 1.00 1.00
Former smoker (>5 years) 71 124 1.51 (0.96-2.36) 1.34 (0.85-2.12)
Smoker 32 57 1.22 (0.70-2.14) 1.13 (0.63 -2.02)
Total pack-years of smoking
0 59 145 1.00 1.00
1-19 24 62 1.04 (0.59-1.85) 1.00 (0.56-1.80)
20- 39 36 53 1.68 (0.98-2.88) 1.56 (0.89-2.72)
>40 43 66 1.53 (0.91-2.59) 1.28 (0.74-2.22)
P value for trend 0.05 0.19
aAdjusted for age, gender and family history ofcolorectal cancer. bAdjusted for age, gender, family history ofcolorectal cancer, body mass index
and alcohol, cruciferous vegetables and meat consumption.
Variable
Gender
Male
Female
Age (years)
<55
55 -64
65-74
>75
TNM Stage
0/I
II
III
IVSmoking and p53 In colorectal cancer
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Table Ill Association between p53 overexpression and smoking in colorectal cancer
p53+ cases p53- cases OR (95% CI)a OR (95% CI)b
Smoking status
Non-smoker 33 26 1.00 1.00
Former smoker (>5 years) 30 41 0.61 (0.29-1.30) 0.60 (0.28-1.31)
Smoker 9 23 0.35 (0.35-0.95) 0.35 (0.12-0.98)
Total pack-years of smoking
0 33 26 1.00 1.00
1-19 12 12 0.87 (0.32-2.38) 0.92 (0.33-2.61)
20-39 10 26 0.30 (0.11-0.77) 0.30 (0.11-0.78)
>40 17 26 0.58 (0.24-1.37) 0.55 (0.22-1.37)
P value for trend 0.07 0.06
aAdjusted for age, gender, family history ofcolorectal cancer and hospital ofdiagnosis. bAdjusted for age, gender, family history of colorectal
cancer, hospital ofdiagnosis, body mass index and alcohol, cruciferous vegetables and meat consumption.
Table IV Risk of developing a colorectal tumour for smoking status and total pack-years of smoking by p53 overexpression
p53 + tumour p53- tumour
pS3 + pS3-
cases cases Controls OR (95% CI)' OR (95% CI)" OR (95% CI)- OR (95% CI)
Smoking status
Non-smoker 33 26 145 1.00 1.00 1.00 1.00
Former smoker 30 41 124 1.09 (0.61-1.95) 0.95 (0.52-1.73) 2.07 (1.15-3.74) 1.84 (1.00-3.37)
(>5 years)
Smoker 9 23 57 0.68 (0.30-1.54) 0.63 (0.27-1.46) 1.94 (0.97-3.85) 1.78 (0.88-3.61)
Total pack-years
of smoking
0 33 26 145 1.00 1.00 1.00 1.00
1-19 12 12 62 0.92 (0.44-1.92) 0.87 (0.41-1.84) 1.21 (0.56-2.61) 1.17 (0.53-2.57)
20-39 10 26 53 0.81 (0.37-1.79) 0.72 (0.32-1.64) 2.87 (1.49-5.56) 2.72 (1.38-5.36)
40 17 26 66 1.10 (0.55-2.18) 0.92 (0.45-1.92) 2.09 (1.07-4.10) 1.68 (0.83-3.39)
P-value for trend 0.94 0.68 0.005 0.03
aAdjusted for age, gender andfamily history ofcolorectal cancer. bAdjusted for age, gender, family history ofcolorectal cancer, body mass index
and alcohol, cruciferous vegetables and meat consumption.
with at least 35 years of smoking. These results suggest that
earlier studies of colorectal cancer risk and smoking are
inconsistent because they failed to allow for an adequate
induction period. In addition, these results suggest that
smoking may act as an initiator of colorectal carcinogenesis,
causing mutations in genes that occur early in the adenoma-
carcinoma sequence (e.g. apc, ras). The fact that individuals
born with a mutated apc gene (familial adenomatous
polyposis) require an average of 35 years for their adenomas
to convert to carcinoma supports this hypothesis. Moreover,
since smoking within the past 35 years was related to
adenoma formation but not to cancer risk, smoking is
unlikely to directly influence mutations that occur late in the
progression from adenoma to carcinoma. These findings
imply that studies of colorectal cancer risk and smoking may
be biased by the inclusion of cases whose tumours develop
gene mutations late in the adenoma-carcinoma sequence and
may not be directly associated with smoking.
The p53 tumour-suppressor gene is the most common
genetic abnormality found in colorectal cancer (Fearon,
1993). Mutation and overexpression of p53 occurs late in
colorectal carcinogenesis, before the transition of an adenoma
to a carcinoma (Fearon, 1993). Carcinogens present in
tobacco smoke cause DNA damage and may influence
TP53 pathways in many human cancers. Associations
between p53 mutation/overexpression and tobacco smoking
have been observed in tumour sites where this mutation is an
early occurrence in the progression to carcinoma such as lung
(Suzuki et al., 1992; Miller et al., 1992), head and neck (Field
et al., 1991, 1994), oesophagus (Hollstein et al., 1991b) and
bladder (Spruck et al., 1993; Zhang et al., 1994a), but not
those where p53 is a late occurrence such as stomach (Zhang
et al., 1995a) and prostate (Zhang et al., 1994b). Zhang et al.
(1995b) recently reported no obvious association between
tobacco smoking and p53 nuclear expression in colorectal
cancer. However, the study had a relatively small sample size
and included only patients with Duke's C stage neoplasms.
To investigate the relationship between p53 overexpression
and smoking exposure in colorectal cancer, we analysed
tumour specimens for p53 protein and categorised them
according to the patient's smoking exposure. Case series
analysis suggested aetiological heterogeneity for p53 over-
expression and smoking exposure and may indicate the
presence of distinct causal mechanisms for p53+ cases and
p53- cases. To estimate the individual relative risks of
developing a p53+ versus a p53- tumour we used a healthy
control group. We observed that tumours developing through
a p53+-dependent pathway were unrelated to smoking
exposures. However, those tumours developing through a
p53 independent pathway were significantly associated with
both smoking status and total pack-years of smoking (trend
test: P=0.03). These data may suggest that smoking may
initiate tumour mutations early in the adenoma-carcinoma
sequence, perhaps in apc or ras genes (Fearon and Vogelstein,
1990), that do not require p53 mutation/overexpression to
progress from an adenoma to a carcinoma. This also may
explain conflicting results between risk of colorectal
adenomas and carcinoma relative to smoking exposure.
The p53 gene is considered a common target in human
carcinogenesis and mutations of this gene may inactivate
their encoded mutant proteins. Many studies have observed a
high correlation between p53 gene missense mutation and
immunohistochemical detection of p53 overexpression
(Cordon-Cardo et al., 1994; Umekita et al., 1994).a. ad p53 i ceiobct caner
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However, the absence of p53 overexpression does not
necessarily imply the absence of p53 mutations, since
tumours with frameshift or null mutations may have
undetectable levels of p53 protein, although only 8% of all
colorectal tumours display this type of alteration (Greenblatt
et al., 1994). Therefore, misclassification of p53 protein
overexpression status as it relates to the underlying mutation
is likely to be small in colorectal tumours.
Jones et al. (1991) suggested that there are two general
patterns of p53 mutations: mutations induced by exogenous
carcinogens, and those occurring spontaneously due to
endogenous mutagens. Carcinogen-induced mutations are
caused by direct interaction of carcinogens with DNA,
leading to specific point mutations, predominantly transver-
sions. For example, a study of p53 mutations in non-small
cell lung carcinomas found that most mutations were
transversions at G and C residues (Chiba et al., 1990). This
suggests that lung cancer results from the direct interaction of
carcinogens in cigarette smoke with DNA.
Spontaneous mutations arise at CpG dinucleotides, which
are thought to result from the frequent methylation of the
cytosine residue in CpG sites with a high frequency of
transitions. These spontaneous mutations are assumed to
result from an endogenous process, as no exogenous factors
have been identified. In colorectal cancer, most p53
mutations are spontaneous with transitions occurring at
CpG sites. However, a small percentage of p53 mutations in
colorectal cancer are transversions or occur at non-CpG sites,
and may result from an exogenous carcinogen. If we assume
that p53 overexpression indicates mutation, it is possible that
although the majority of our p53+ cases may be unrelated to
smoking (CpG transitions), a small percentage of p53-
tumours (transversions) may be associated with tobacco
use. Ideally, future studies should employ immunohistochem-
ical detection of p53 overexpression along with sequence
analysis to examine these associations.
The exact mechanism by which cigarette smoking
influences colorectal carcinogenesis is unclear. Smoking
increases the risk at several cancer sites not directly in
contact with smoke including pancreas, stomach, kidney and
bladder (US Department of Health, Education, and Welfare,
1979). Carcinogens in smoke could affect the mucosa of the
large bowel through direct ingestion or through the
circulatory system. Polycyclic aromatic hydrocarbons
(PAHs) and heterocyclic amines are two potent carcinogens
found in cigarette smoke and are also observed in well-done
meat, another risk factor for colorectal cancer (Laden et al.,
1995).
The possibility exists that cigarette smokers consume a diet
consisting of fewer protective and more numerous carcino-
genic agents. Smokers generally have lower intakes of fruits
and vegetables and higher intakes of fats than non-smokers
(Subar and Harlan, 1993). Therefore, the association between
p53 (negative) independent tumours and smoking may be
confounded by dietary factors associated with this pathway.
However in our analysis, a statistically significant dose-
response relationship for the association between p53
negative patients and total pack-years of smoking existed
(trend test: P=0.03), even after adjustment for alcohol, meat,
cruciferous vegetables and body mass index. Therefore, it is
unlikely that confounding by diet completely accounts for the
association between cigarette smoking and the p53 indepen-
dent pathway.
The use of hospital/screening clinic controls in a case-
control comparison may lead to bias since controls may
overrepresent healthier lifestyles. However, the odds ratios
observed in our case-control comparison are similar to those
reported in three recent population-based cohort studies
(Giovannucci et al., 1994a and b; Heineman et al., 1995).
Additionally, the primary use ofthis control group is to assist
in the estimation of the individual relative risks for p53
positive and p53 negative tumour development separately, for
smoking exposure variables. This bias is of less concern in
our case series analysis since patients are unaware of their
p53 status.
The positive consistent finding that smoking increases the
risk ofcolorectal adenoma formation but not cancer has been
problematic. Our results suggest that results of studies of
colorectal cancer risk and smoking may be affected by
inclusion of patients whose tumours harbour p53 genetic
alterations that occur late in the adenoma-carcinoma
sequence, that are unrelated to smoking history. In
addition, smoking was significantly associated in tumours
developing through a p53 independent pathway, perhaps the
result of initiation of mutations in genes early in the
carcinogenic process that do not need a p53 alteration to
progress from an adenoma to a carcinoma.
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